Ethic Inc. boosted its stake in Zoetis Inc. (NYSE:ZTS – Free Report) by 56.9% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 64,000 shares of the company’s stock after purchasing an additional 23,204 shares during the quarter. Ethic Inc.’s holdings in Zoetis were worth $4,469,000 as of its most recent filing with the Securities & Exchange Commission.
Several other hedge funds also recently bought and sold shares of ZTS. Valmark Advisers Inc. lifted its stake in Zoetis by 7.7% in the 1st quarter. Valmark Advisers Inc. now owns 1,747 shares of the company’s stock worth $207,000 after purchasing an additional 125 shares in the last quarter. Balefire LLC increased its holdings in shares of Zoetis by 6.7% in the first quarter. Balefire LLC now owns 1,996 shares of the company’s stock worth $236,000 after purchasing an additional 125 shares during the period. Greenleaf Trust raised its position in shares of Zoetis by 2.9% in the second quarter. Greenleaf Trust now owns 4,763 shares of the company’s stock worth $342,000 after buying an additional 134 shares in the last quarter. Financial Solutions Advisory Group Inc. raised its position in shares of Zoetis by 1.1% in the third quarter. Financial Solutions Advisory Group Inc. now owns 15,697 shares of the company’s stock worth $1,096,000 after buying an additional 170 shares in the last quarter. Finally, 71 West Capital Partners boosted its stake in Zoetis by 6.6% during the second quarter. 71 West Capital Partners now owns 2,823 shares of the company’s stock valued at $203,000 after buying an additional 175 shares during the period. Hedge funds and other institutional investors own 92.80% of the company’s stock.
Analyst Ratings Changes
Several equities analysts recently commented on the company. Piper Sandler reduced their target price on Zoetis from $90.00 to $80.00 and set a “neutral” rating for the company in a research report on Monday, August 10th. Morgan Stanley lowered their price target on Zoetis from $85.00 to $82.00 and set an “overweight” rating on the stock in a report on Thursday, October 29th. Citigroup dropped their price target on Zoetis from $112.00 to $96.00 and set a “buy” rating for the company in a research report on Tuesday, August 11th. TD Cowen cut their price objective on Zoetis from $104.00 to $94.00 and set a “buy” rating for the company in a report on Tuesday, August 25th. Finally, Zacks Research upgraded shares of Zoetis from a “strong sell” rating to a “hold” rating in a research report on Monday, October 26th. Eight equities research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $101.25.
Get Our Latest Research Report on Zoetis
Zoetis Stock Up 0.2%
Shares of NYSE:ZTS opened at $82.48 on Wednesday. The firm has a market capitalization of $33.51 billion, a PE ratio of 14.03, a price-to-earnings-growth ratio of 1.19 and a beta of 0.67. The company has a debt-to-equity ratio of 2.51, a quick ratio of 1.40 and a current ratio of 2.35. Zoetis Inc. has a 52-week low of $68.77 and a 52-week high of $132.49. The firm has a fifty day moving average of $75.88 and a 200 day moving average of $92.18.
Zoetis (NYSE:ZTS – Get Free Report) last released its quarterly earnings results on Thursday, November 5th. The company reported $1.75 earnings per share for the quarter, beating analysts’ consensus estimates of $1.51 by $0.24. Zoetis had a return on equity of 85.90% and a net margin of 26.15%. The business had revenue of $2.39 billion for the quarter, compared to the consensus estimate of $2.30 billion. During the same quarter last year, the business posted $1.70 earnings per share. The company’s revenue for the quarter was down 1.3% on a year-over-year basis. As a group, research analysts anticipate that Zoetis Inc. will post 6.29 EPS for the current fiscal year.
Zoetis Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 1st. Stockholders of record on Friday, October 30th will be given a dividend of $0.53 per share. The ex-dividend date is Friday, October 30th. This represents a $2.12 annualized dividend and a dividend yield of 2.6%. Zoetis’s dividend payout ratio is 36.05%.
Zoetis Company Profile
Zoetis is an animal health company that discovers, develops, manufactures and markets medicines, vaccines, diagnostic products and other services for animals. Its products support both companion animals, such as dogs and cats, and livestock, including cattle, pigs, poultry, sheep and fish. The company’s offerings include treatments for pain, infections and skin conditions, as well as vaccines, parasiticides, diagnostic tools and genetic testing services. Zoetis serves veterinarians, livestock producers and other animal health professionals around the world.
Further Reading
- Five stocks we like better than Zoetis
- Why Kinder Morgan’s Chairman Just Bought $15 Million in Stock
- Rocket Lab’s Record Backlog Could Fuel a Rebound, But Neutron Raises the Stakes
- Don’t Let Their Low Yields Fool You: 3 Dividend Stocks Worth Watching
- A $4 Billion Jolt: NRG Energy Powers Data Center Ambitions
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS – Free Report).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.
